GTCM
GBT

Gyon Technologies Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Gyon Technologies Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,199
Closed -$457K – 587
2022
Q1 		$457K Sell
13,199
-14,813
-53% -$443K 0.32% 109
2021
Q4 		$820K Buy
+28,012
New +$868K 0.15% 193

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Gyon Technologies Capital Management's GBT Position: Q2 2022 in Review

Gyon Technologies Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2022, closing a stake of 13,199 shares — an estimated $457K sold.

Gyon Technologies Capital Management first reported a position in GBT in Q4 2021 and held it in 2 quarters. The position peaked at $820K in Q4 2021. 195 funds tracked by Wall St. Rank hold GBT as of Q2 2022.

  • Gyon Technologies Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 13,199 Global Blood Therapeutics, Inc. shares in Q2 2022, an estimated $457K.
  • Gyon Technologies Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2021 and held it in 2 quarters.
  • Gyon Technologies Capital Management's Global Blood Therapeutics, Inc. position peaked at $820K in Q4 2021.
  • 195 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.